Baminercept  (Synonyms: BG 9924; TT-47)

Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome^[1][2].

Baminercept (100 mg/kg) induces maternal liver toxicity in some pregnant rats, but shows no such effect in cynomolgus monkeys or non-pregnant rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

93.76 kDa

909110-25-4

Liquid

Colorless to light yellow

[Baminercept]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [LTBR (lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily (TNFR)member 3, TNFCR)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized TNF-beta/TNFSF1 Protein, Human (HY-P7304) can bind Baminercept. The EC₅₀ for this effect is 16.53 ng/mL.

• [1]. Bienkowska J, et al. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One. 2014;9(11):e112545. Published 2014 Nov 18.  [Content Brief]

  [2]. St. Clair E W, et al. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double‐Blind, Placebo‐Controlled Trial[J]. Arthritis & Rheumatology, 2018, 70(9): 1470-1480.